Checkpoint Therapeutics

CKPT49

Penny Stock

$3.16arrow_drop_down0.62%-$0.02

Penny Stock

CKPT49

$3.16

arrow_drop_down0.62%-$0.02

Penny Stock

Performance History

Key Stats
Open	$3.00
Prev. Close	$2.97
EPS	-1.71
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$135.50M
PE Ratio	-

	LOW	HIGH
Day Range	2.92	3.09
52 Week Range	1.36	3.62

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-1.71

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Checkpoint Therapeutics (CKPT)

Checkpoint Therapeutics Inc is a biopharmaceutical company that focuses on the development and commercialization of immune-enhanced combination therapies for the treatment of cancer. The company's lead product candidate, CK-101, is an inhibitor of the epidermal growth factor receptor (EGFR), which is being evaluated in a Phase 1/2 clinical trial in patients with advanced non-small cell lung cancer (NSCLC). CK-101 has demonstrated promising activity in preclinical models, and the ongoing clinical trial aims to assess its safety and efficacy in NSCLC patients. In addition to CK-101, Checkpoint Therapeutics is also developing CK-301, an anti-programmed death ligand 1 (PD-L1) antibody, as a potential treatment for multiple cancers. CK-301 is currently being evaluated in a Phase 1 clinical trial in patients with selected solid tumors.

The market cap of Checkpoint Therapeutics Inc is currently __MARKET_CAP___. The company's stock, CKPT, has experienced fluctuations over the past year, with a 52-week range of __52_WEEK_RANGE__. As of the latest trading session, the stock had a day range of __DAY_RANGE__ and a trading volume of __TRADING_VOLUME___. It is important to note that the stock price history of Checkpoint Therapeutics Inc can be influenced by various factors, including clinical trial results, regulatory approvals, and market trends. Investors should carefully consider these factors before making any investment decisions.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. James F. Oliviero III, C.F.A., CFA
Headquarters: Waltham
Employees: 24
Exchange: NASDAQ

add Checkpoint Therapeutics to watchlist

Keep an eye on Checkpoint Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Checkpoint Therapeutics 's (CKPT) price per share?

The current price per share for Checkpoint Therapeutics (CKPT) is $3.16. The stock has seen a price change of -$0.02 recently, indicating a -0.63% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Checkpoint Therapeutics (CKPT)?

For Checkpoint Therapeutics (CKPT), the 52-week high is $3.62, which is 14.56% from the current price. The 52-week low is $1.36, the current price is 132.35% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Checkpoint Therapeutics (CKPT) a growth stock?

Checkpoint Therapeutics (CKPT) has shown an average price growth of -2.84% over the past three years. It has received a score of 15 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Checkpoint Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Checkpoint Therapeutics (CKPT) stock price performance year to date (YTD)?

As of the latest data, Checkpoint Therapeutics (CKPT) has a year-to-date price change of 44.29%. Over the past month, the stock has experienced a price change of 33.9%. Over the last three months, the change has been 26.91%. Over the past six months, the figure is 117.93%. Looking at a longer horizon, the five-year price change stands at -84.2%.

help

Is Checkpoint Therapeutics (CKPT) a profitable company?

Checkpoint Therapeutics (CKPT) has a net income of -$51.85M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -16.28K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$52.15M. Furthermore, the EBITDA is $0.

help

What is the market capitalization of Checkpoint Therapeutics (CKPT)?

Checkpoint Therapeutics (CKPT) has a market capitalization of $135.5M. The average daily trading volume is 3.16, indicating the stock's liquidity and investor engagement.